Exact Mass: 359.2243

Exact Mass Matches: 359.2243

Found 125 metabolites which its exact mass value is equals to given mass value 359.2243, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Lavoltidine

{1-methyl-5-[(3-{3-[(piperidin-1-yl)methyl]phenoxy}propyl)amino]-1H-1,2,4-triazol-3-yl}methanol

C19H29N5O2 (359.2321)


C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists

   

Undecanedioylcarnitine

3-[(10-carboxydecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H33NO6 (359.2308)


Undecanedioylcarnitine is an acylcarnitine. More specifically, it is an undecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undecanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undecanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Gepirone

4,4-dimethyl-1-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}piperidine-2,6-dione

C19H29N5O2 (359.2321)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants Gepirone is a selective and affinitive 5-HT1A agonist. Gepirone binds selectively to 5-HT1A receptor binding site. Gepirone acts as an antidepressant agent can be used for anxiety and major depressive disorder research[1].

   

Glycyllysylarginine

2-({6-amino-2-[(2-amino-1-hydroxyethylidene)amino]-1-hydroxyhexylidene}amino)-5-carbamimidamidopentanoate

C14H29N7O4 (359.2281)


   
   

Broussonetine H

Broussonetine H

C18H33NO6 (359.2308)


   
   

Broussonetine G

Broussonetine G

C18H33NO6 (359.2308)


   

Broussonetine N

Broussonetine N

C18H33NO6 (359.2308)


   

ambiguine P

ambiguine P

C25H29NO (359.2249)


   

arginylglycyllysine

arginylglycyllysine

C14H29N7O4 (359.2281)


   

glycyllysylarginine

glycyllysylarginine

C14H29N7O4 (359.2281)


   

valylasparagyllysine

valylasparagyllysine

C15H29N5O5 (359.2169)


   
   
   

glycylarginyllysine

glycylarginyllysine

C14H29N7O4 (359.2281)


   
   
   

asparagylvalyllysine

asparagylvalyllysine

C15H29N5O5 (359.2169)


   
   

Ala Ala Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]propanamido]hexanoic acid

C15H29N5O5 (359.2169)


   

Ala Ala Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]hexanamido]propanoic acid

C15H29N5O5 (359.2169)


   

Ala Lys Ala Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]propanamido]propanoic acid

C15H29N5O5 (359.2169)


   

Gly Gly Lys Val

(2S)-2-[(2S)-6-amino-2-[2-(2-aminoacetamido)acetamido]hexanamido]-3-methylbutanoic acid

C15H29N5O5 (359.2169)


   

Gly Gly Val Lys

(2S)-6-amino-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-methylbutanamido]hexanoic acid

C15H29N5O5 (359.2169)


   

Gly Lys Gly Val

(2S)-2-{2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]acetamido}-3-methylbutanoic acid

C15H29N5O5 (359.2169)


   

Gly Lys Val Gly

2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-methylbutanamido]acetic acid

C15H29N5O5 (359.2169)


   

Gly Val Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]acetamido}hexanoic acid

C15H29N5O5 (359.2169)


   

Gly Val Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]hexanamido]acetic acid

C15H29N5O5 (359.2169)


   
   
   

Lys Ala Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]propanamido]propanoic acid

C15H29N5O5 (359.2169)


   

Lys Gly Gly Val

(2S)-2-(2-{2-[(2S)-2,6-diaminohexanamido]acetamido}acetamido)-3-methylbutanoic acid

C15H29N5O5 (359.2169)


   

Lys Gly Val Gly

2-[(2S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-methylbutanamido]acetic acid

C15H29N5O5 (359.2169)


   

Lys Val Gly Gly

2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]acetamido}acetic acid

C15H29N5O5 (359.2169)


   
   
   
   
   
   

Val Gly Gly Lys

(2S)-6-amino-2-(2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}acetamido)hexanoic acid

C15H29N5O5 (359.2169)


   

Val Gly Lys Gly

2-[(2S)-6-amino-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}hexanamido]acetic acid

C15H29N5O5 (359.2169)


   

Val Lys Gly Gly

2-{2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]acetamido}acetic acid

C15H29N5O5 (359.2169)


   

tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

C20H30BNO4 (359.2268)


   

Tert-Butyl 6-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-Yl)-3,4-Dihydroisoquinoline-2(1H)-Carboxylate

Tert-Butyl 6-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-Yl)-3,4-Dihydroisoquinoline-2(1H)-Carboxylate

C20H30BNO4 (359.2268)


   

Glucagon receptor antagonists-2

Glucagon receptor antagonists-2

C22H30FNO2 (359.226)


   

Glucagon receptor antagonists-3

Glucagon receptor antagonists-3

C22H30FNO2 (359.226)


   

D-Leucyl-N-(4-Carbamimidoylbenzyl)-L-Prolinamide

D-Leucyl-N-(4-Carbamimidoylbenzyl)-L-Prolinamide

C19H29N5O2 (359.2321)


   

cannabigerolate

cannabigerolate

C22H31O4- (359.2222)


A dihydroxybenzoate that is the conjugate base of cannabigerolic acid, obtained by deprotonation of the carboxy group.

   

Cannabinerolate

Cannabinerolate

C22H31O4- (359.2222)


A dihydroxybenzoate that is the conjugate base of cannabinerolic acid, obtained by deprotonation of the carboxy group.

   

(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosa-4,7,10,13,15,19-hexaenoate

(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosa-4,7,10,13,15,19-hexaenoate

C22H31O4- (359.2222)


   

9alpha-Hydroxy-3-oxo-23,24-bisnorchol-4-en-22-oate

9alpha-Hydroxy-3-oxo-23,24-bisnorchol-4-en-22-oate

C22H31O4- (359.2222)


   

17R-hydroperoxydocosahexaenoate

17R-hydroperoxydocosahexaenoate

C22H31O4- (359.2222)


   

Pregn-4-en-3-one-22-oate

Pregn-4-en-3-one-22-oate

C22H31O4- (359.2222)


   

Undecanedioylcarnitine

Undecanedioylcarnitine

C18H33NO6 (359.2308)


   
   

14-Hpdhe(1-)

14-Hpdhe(1-)

C22H31O4- (359.2222)


A polyunsaturated fatty acid anion that is the conjugate base of 14-HPDHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

14(S)-Hpdhe(1-)

14(S)-Hpdhe(1-)

C22H31O4- (359.2222)


A polyunsaturated fatty acid anion that is the conjugate base of 14(S)-HPDHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

N-[3-(1-azepanyl)propyl]-1-ethylsulfonyl-4-piperidinecarboxamide

N-[3-(1-azepanyl)propyl]-1-ethylsulfonyl-4-piperidinecarboxamide

C17H33N3O3S (359.2243)


   

(13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate

(13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222)


A docosanoid anion that is the conjugate base of (13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   

11S-HpDHA(1-)

11S-HpDHA(1-)

C22H31O4- (359.2222)


   

(4Z,7Z,11E,13Z,16Z,19Z)-10-hydroperoxydocosa-4,7,11,13,16,19-hexaenoate

(4Z,7Z,11E,13Z,16Z,19Z)-10-hydroperoxydocosa-4,7,11,13,16,19-hexaenoate

C22H31O4- (359.2222)


   
   

Glycyl-lysyl-arginine

Glycyl-lysyl-arginine

C14H29N7O4 (359.2281)


   
   
   
   
   
   
   
   
   
   
   
   
   
   

neuroprotectin D1 anion

neuroprotectin D1 anion

C22H31O4- (359.2222)


   

(4Z,7S,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoate

(4Z,7S,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoate

C22H31O4- (359.2222)


   

7S,14S-diHDHA(1-)

7S,14S-diHDHA(1-)

C22H31O4- (359.2222)


   

(5Z,7S,8E,10Z,13Z,15Z,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoate

(5Z,7S,8E,10Z,13Z,15Z,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoate

C22H31O4- (359.2222)


   

(4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosa-4,8,10,12,16,19-hexaenoate

(4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosa-4,8,10,12,16,19-hexaenoate

C22H31O4- (359.2222)


   

10(R),17(R)-dihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoate

10(R),17(R)-dihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoate

C22H31O4- (359.2222)


   

(14S,21R)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

(14S,21R)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222)


   

(14R,21R)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

(14R,21R)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222)


   

(14S,21S)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

(14S,21S)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222)


   

(14R,21S)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

(14R,21S)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222)


   

6-{3-[(1E,3E,5Z,7E,11Z)-9-hydroxytetradeca-1,3,5,7,11-pentaen-1-yl]oxiran-2-yl}hexanoate

6-{3-[(1E,3E,5Z,7E,11Z)-9-hydroxytetradeca-1,3,5,7,11-pentaen-1-yl]oxiran-2-yl}hexanoate

C22H31O4- (359.2222)


   

(7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoate

(7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222)


   

7S,17S-diHDHA(1-)

7S,17S-diHDHA(1-)

C22H31O4- (359.2222)


   

2-(3-Hydroxybutoxy)-N-(2-diethylaminoethyl)-4-quinolinecarboxamide

2-(3-Hydroxybutoxy)-N-(2-diethylaminoethyl)-4-quinolinecarboxamide

C20H29N3O3 (359.2209)


   

gepirone

gepirone

C19H29N5O2 (359.2321)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants Gepirone is a selective and affinitive 5-HT1A agonist. Gepirone binds selectively to 5-HT1A receptor binding site. Gepirone acts as an antidepressant agent can be used for anxiety and major depressive disorder research[1].

   

loxtidine

LAVOLTIDINE

C19H29N5O2 (359.2321)


C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists

   

(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosahexaenoate

(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosahexaenoate

C22H31O4 (359.2222)


A hydroperoxydocosahexaenoate that is the conjugate base of (17S)-HPDoHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoate

C22H31O4 (359.2222)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(7S,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoate

(7S,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoate

C22H31O4 (359.2222)


A dihydroxydocosahexaenoate that is the conjugate base of (7S,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

resolvin D5(1-)

resolvin D5(1-)

C22H31O4 (359.2222)


A dihydroxydocosahexaenoate that is the conjugate base of resolvin D5, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosahexaenoate

(4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosahexaenoate

C22H31O4 (359.2222)


A docosanoid anion that is the conjugate base of (4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoate

C22H31O4 (359.2222)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

7,8-epoxy,17-hydroxy-(9E,11E,13Z,15E,19Z)-docosapentaenoate

7,8-epoxy,17-hydroxy-(9E,11E,13Z,15E,19Z)-docosapentaenoate

C22H31O4 (359.2222)


A docosanoid anion that is the conjugate base of 7,8-epoxy,17-hydroxy-(9E,11E,13Z,15E,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

aspirin-triggered protectin D1(1-)

aspirin-triggered protectin D1(1-)

C22H31O4 (359.2222)


A dihydroxydocosahexaenoate that is the conjugate base of aspirin-triggered protectin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoate

C22H31O4 (359.2222)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,12E,14S,16Z,19Z,21S)-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14S,16Z,19Z,21S)-dihydroxydocosahexaenoate

C22H31O4 (359.2222)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14S,16Z,19Z,21S)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoate

C22H31O4 (359.2222)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

asperparaline A

asperparaline A

C20H29N3O3 (359.2209)


An alkaloid isolated from Aspergillus aculeatus.

   

protectin D1(1-)

protectin D1(1-)

C22H31O4 (359.2222)


A dihydroxydocosahexaenoate that is the conjugate base of protectin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoate

C22H31O4 (359.2222)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   
   

1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

C20H29N3O3 (359.2209)


   

(1's,3s,3's,7'r,12's)-1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

(1's,3s,3's,7'r,12's)-1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

C20H29N3O3 (359.2209)


   

(1'r,3s,3's,7'r,12's)-1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

(1'r,3s,3's,7'r,12's)-1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

C20H29N3O3 (359.2209)


   

(4s)-4-[(1z,5e,7e,11r)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole

(4s)-4-[(1z,5e,7e,11r)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole

C22H33NOS (359.2283)


   

4-(11-methoxytetradeca-1,5,7,13-tetraen-1-yl)-2-(2-methylcyclopropyl)-4,5-dihydro-1,3-thiazole

4-(11-methoxytetradeca-1,5,7,13-tetraen-1-yl)-2-(2-methylcyclopropyl)-4,5-dihydro-1,3-thiazole

C22H33NOS (359.2283)


   

(2s)-n-[(2s)-1-(1h-indol-3-yl)-3-(propanoyloxy)propan-2-yl]-3-methyl-2-(methylamino)butanimidic acid

(2s)-n-[(2s)-1-(1h-indol-3-yl)-3-(propanoyloxy)propan-2-yl]-3-methyl-2-(methylamino)butanimidic acid

C20H29N3O3 (359.2209)


   

(2r,3r,4r,5r)-2-[(1r)-5-{1,6-dioxaspiro[4.5]decan-7-yl}-1-hydroxypentyl]-5-(hydroxymethyl)pyrrolidine-3,4-diol

(2r,3r,4r,5r)-2-[(1r)-5-{1,6-dioxaspiro[4.5]decan-7-yl}-1-hydroxypentyl]-5-(hydroxymethyl)pyrrolidine-3,4-diol

C18H33NO6 (359.2308)


   

(4r)-4-[(1z,5e,7e,11r)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole

(4r)-4-[(1z,5e,7e,11r)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole

C22H33NOS (359.2283)


   

4-[(1e,5e,7e,11r)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole

4-[(1e,5e,7e,11r)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole

C22H33NOS (359.2283)


   

(10r)-10-[(3s,5r,6r,7r,7ar)-6,7-dihydroxy-5-(hydroxymethyl)-hexahydro-1h-pyrrolizin-3-yl]-1,10-dihydroxydecan-5-one

(10r)-10-[(3s,5r,6r,7r,7ar)-6,7-dihydroxy-5-(hydroxymethyl)-hexahydro-1h-pyrrolizin-3-yl]-1,10-dihydroxydecan-5-one

C18H33NO6 (359.2308)


   

4-[(1z,5e,7e)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole

4-[(1z,5e,7e)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole

C22H33NOS (359.2283)


   

(2r,3r,4r,5r)-2-[(1r)-4-{1,7-dioxaspiro[5.5]undecan-2-yl}-1-hydroxybutyl]-5-(hydroxymethyl)pyrrolidine-3,4-diol

(2r,3r,4r,5r)-2-[(1r)-4-{1,7-dioxaspiro[5.5]undecan-2-yl}-1-hydroxybutyl]-5-(hydroxymethyl)pyrrolidine-3,4-diol

C18H33NO6 (359.2308)


   

10-[6,7-dihydroxy-5-(hydroxymethyl)-hexahydro-1h-pyrrolizin-3-yl]-1,10-dihydroxydecan-5-one

10-[6,7-dihydroxy-5-(hydroxymethyl)-hexahydro-1h-pyrrolizin-3-yl]-1,10-dihydroxydecan-5-one

C18H33NO6 (359.2308)


   

(1'r,3s,3's,7's,12's)-1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

(1'r,3s,3's,7's,12's)-1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

C20H29N3O3 (359.2209)


   

(10r)-10-[(3s,5r,6r,7r)-6,7-dihydroxy-5-(hydroxymethyl)-hexahydro-1h-pyrrolizin-3-yl]-1,10-dihydroxydecan-5-one

(10r)-10-[(3s,5r,6r,7r)-6,7-dihydroxy-5-(hydroxymethyl)-hexahydro-1h-pyrrolizin-3-yl]-1,10-dihydroxydecan-5-one

C18H33NO6 (359.2308)